NCT06958198View on ClinicalTrials.gov

"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a Multi-stage Malaria Vaccine)"

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Malaria,Falciparum
Interventions
BIOLOGICAL

R21

A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein

BIOLOGICAL

RH5.1

A soluble protein vaccine against the RH5 antigen

BIOLOGICAL

R78C

A soluble RIPR EGF-CyRPA fusion protein vaccine

BIOLOGICAL

Matrix-M™

A saponin-based vaccine adjuvant

Trial Locations (1)

BP 7192 OUAGADOUGOU 03, BF

Institut de Recherche en Sciences de la Santé, Siglé

All Listed Sponsors
lead

University of Oxford

OTHER

collaborator

Institut de Recherche en Sciences de la Sante, Burkina Faso

OTHER_GOV

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

collaborator

Wellcome Trust

OTHER